John Clark

Senior Director Of Plant Operations at Aytu BioScience

John Clark has a diverse work experience in the pharmaceutical industry. John is currently the Senior Director of Plant Operations at Aytu BioPharma. Before that, they held the position of Director of Engineering at iBio, Inc., where they led the transformation of the facility for commercial scale manufacturing. Prior to that, they were the Senior Director of Technical Services/Plant Operations at Neos Therapeutics, Inc., where they played a key role in the scale-up, process development, and validation of manufacturing and packaging processes. John also served as the Senior Director of Plant Operations at Neos Therapeutics, where they led the manufacturing, packaging, engineering, and maintenance groups. Earlier in their career, they held roles such as Director of Research and Development and Director of Engineering at Neos Therapeutics, and Validation Manager at Cardinal/Adams Respiratory Therapeutics. John also had experience as a Quality Assurance Validation Manager at Yamanouchi Pharma Technologies and as the President of a Pharmaceutical Validation Consulting firm. Their expertise includes site master planning, validation planning, budgeting, and project management.

John Clark completed their education with a Bachelor of Science degree in Chemistry from East Carolina University from 1983 to 1987. John then pursued a degree in Computer Programming, earning an Associate of Applied Science from Johnston Community College from 2000 to 2003. Lastly, they earned a Master of Science in Engineering and Technology Management from Oklahoma State University from 2004 to 2006.

Location

Dallas, United States

Links

Previous companies


Org chart

No direct reports

Teams


Offices

This person is not in any offices


Aytu BioScience

2 followers

Aytu BioPharma (NASDAQ: AYTU) is a specialty pharmaceutical company with a growing commercial portfolio of prescription therapeutics and consumer health products, including ADHD and pediatrics medications. Their evolution has been driven by strategic in-licensing, acquisition-based transactions and organic product growth. As they continue on this trajectory, they are building a complimentary therapeutic development pipeline that will address significant unmet needs.


Industries

Employees

51-200

Links